COMMUNIQUÉS West-GlobeNewswire

-
Science 37 to be Acquired by eMed, Expanding Access to Patients and Accelerating Enrollment
29/01/2024 - 13:30 -
Alterity Therapeutics to Participate in the ShareCafe Hidden Gems Webinar This Week
29/01/2024 - 13:24 -
SciSparc Announces Initiation of Patient Recruitment for its Clinical Trial with SCI-210 in Children with Autism Spectrum Disorder
29/01/2024 - 13:18 -
Leading Veterinary Software Company Instinct Science Acquires VetMedux, Owner of Fast-Growing Clinician's Brief and Plumb’s Veterinary Drugs
29/01/2024 - 13:18 -
Major shareholder announcement
29/01/2024 - 13:13 -
Tonix Pharmaceuticals Announces Conditional Acceptance of Tonmya™ as Trade Name for TNX-102 SL for the Management of Fibromyalgia
29/01/2024 - 13:00 -
TScan Therapeutics Appoints Seasoned Industry Executive Jason A. Amello as Chief Financial Officer
29/01/2024 - 13:00 -
Gracell Biotechnologies Announces FDA Clearance of IND Application for Phase 1 Clinical Trial of FasTCAR-T GC012F as Early-Line Treatment of Multiple Myeloma
29/01/2024 - 13:00 -
ARMGO Pharma Publishes Positive Phase 1b Trial Results of Rycal® ARM210 for the Treatment of Ryanodine Receptor 1 Related Myopathies
29/01/2024 - 13:00 -
Malaysian Patent Granted for CytoMed Therapeutics' Licensed Allogeneic CAR-Gamma Delta T Cell Technology
29/01/2024 - 13:00 -
Oxford Biomedica completes acquisition of ABL Europe
29/01/2024 - 13:00 -
Applied UV Inc. Announces Receipt of Provisional Patent for Our Pulse Modulated UVC LED System to be Added to Our Patented Fighter Flex LED Solution Expanding Significant Revenue Opportunity
29/01/2024 - 13:00 -
Fortrea Announces Date for Fourth Quarter and Full Year 2023 Financial Results and Conference Call
29/01/2024 - 13:00 -
ANI Pharmaceuticals to Participate at the Guggenheim Healthcare Talks | 6th Annual Biotechnology Conference
29/01/2024 - 12:50 -
21e Guignolée Dr Julien : Montant historique de 4,2 M$ pour les enfants en situation de vulnérabilité
29/01/2024 - 12:45 -
Werth Family Investment Associates Converts Remaining $3.3M of Debt and Accrued Interest into Cingulate Equity at Premium to Market
29/01/2024 - 12:45 -
Oculis to Present at Upcoming February Investor Conferences
29/01/2024 - 12:30 -
KFSH&RC-Madinah Receives Prestigious 2023 Press Ganey Human Experience Guardian of Excellence Award
29/01/2024 - 12:27 -
Vera Therapeutics Announces Proposed Public Offering of Class A Common Stock
29/01/2024 - 12:15
Pages